Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • A New World: Update on Recognizing ADM as an ABMS Subspecialty (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1™ credits while learning about a brief chronology of the origins and current status of the field of addiction medicine. The speakers will also provide an update on the recognition process underway at the time of this presentation. The process of recognition of a new medical field by the American Board of Medical Specialties will be reviewed, with attention to the impact of recognition on existing diplomates and future examination applicants.

    In 1954 Dr. Ruth Fox in New York City set the foundation for the present field of addiction medicine (ADM) when she established the organization now known as the American Society Addiction Medicine (ASAM). ASAM began pursuing recognition for addiction medicine within organized medicine in 1991. In 2007 the American Board of Addiction Medicine (ABAM) was established with the encouragement and facilitation of ASAM, and ABAM then began addressing and fulfilling the recognition requirements by the American Board of Medical Specialties (ABMS)for recognition of the field. By mid-2015 these requirements, which included the establishment of a sufficient number of ADM fellowships, had been fulfilled. ABAM held multiple meetings with ABMS and its member boards. ABPM submitted an application to ABMS for recognition of ADM in May, 2015. A brief history of ABMS, its mission, function and processes, as well as information about its member boards will be reviewed. The history, structure and function of ABPM will be reviewed, with attention to the format and expectations for the new subspecialty. At the time this abstract was submitted, the application from ABPM to ABMS was still under consideration. It is expected that addiction medicine will be a multi-specialty subspecialty open to any physician holding an ABMS primary certificate. There is typically a five-year practice pathway for physician certification in a new field before an ACGME accredited ADM fellowship is required. In this session, ABAM representatives will bring the audience up to date on this process and its outcome. Also covered will be the multiple impacts of formal recognition by ABMS. These include new accommodations expected by health care systems and third party insurers; changes in the education and training environments of all physicians; accreditation of ADM fellowships by the Accreditation Council for Graduate Medical education; the status and future of current ASAM and ABAM certificates; expected eligibility requirements for future ADM certification examinations; anticipated requirements for an ADM MOC program; and a brief history of ACGME, its mission, functions and processes will be reviewed. the importance of ASAM as the leadership organization for physicians practicing addiction medicine. The addiction medicine subspecialty will need a pipeline for fellowship trained physicians, and the ACGME requirements for fellowship accreditation and the plan to establish additional ADM fellowships will be presented. The current fellowships accredited by The ABAM Foundation will be reviewed, with attention to their faculty, fellows and curriculum. The purposed and activities of the ADM Fellowship Director's group will be presented. The session will conclude with a question and answer section.

    Robert Sokol

    MD

    Dr. Robert J. Sokol currently serves as a Distinguished Professor of Obstetrics and Gynecology and Physiology and the John M. Malone, Jr., M.D., Endowed Chair and Director of the C.S. Mott Center for Human Growth and Development at Wayne State University in Detroit, Mich. Dr. Sokol graduated with the highest distinction in philosophy and from medical school with honors from the University of Rochester in New York. After residency training at Washington University/Barnes Hospital in St. Louis, Mo., and after serving as Dr. Willard Allen's last executive Chief Resident, he served in the Air Force as a Major and then completed a fellowship at Maternal-Fetal Medicine, as well as joining the faculty, first at the University of Rochester and then at Metrohealth/Case Western Reserve in Cleveland. He worked his way up to Professor and Director of the Perinatal Clinical Research Center. Recruited as Chair of the Department of Obstetrics and Gynecology at the Wayne State University School of Medicine/Detroit Medical Center in 1983, he served as Dean and Senior Vice President for Medical Affairs from 1988 until 1999. Dr. Sokol is an internationally recognized expert in the area of fetal alcohol spectrum disorders. In 1986, he established and directed the National Institutes of Health-funded WSU Fetal Alcohol Research Center, the only center of its kind in the country at the time. He is currently focused on risk detection and prevention methodology. He is Project Manager II for services in support of the Perinatology Research Branch of the NICHD and was the founding Chair of a University Department of Clinical and Translational Science. He has about 335 referreed papers and about 1500 total publications. He is President Elect of the American Board of Addiction Medicine.

    Patrick O'Connor

    MD, MPH, FACP

    No Biography

    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    William Greaves

    MD. MSPH

    Executive Director, ABPM

  • Developing Fellowship Training Programs to Meet Workforce Needs (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 credit while learning how specialized physician training is the sine qua non of every medical specialty and sub-specialty. Considerable opportunity exists for academic and community physicians who are interested in taking a place in addiction medicine’s future leadership by building new fellowship training programs.

    Specialized physician training is the sine qua non of every medical specialty and sub-specialty. Addiction Medicine is entering a new phase as its fellowship training programs, which have played a central role in the discipline's steady progression toward recognition, assume increasing responsibility for meeting the nation's addiction workforce needs. The more than three dozen fellowships that have been accredited so far by The Addiction Medicine Foundation have laid the groundwork for a national training infrastructure. These programs represent only the first wave toward achieving a target training capacity that is estimated to be in the range of 200-300 fellowship graduates per year. Considerable opportunity exists, therefore, for academic and community physicians who are interested in taking a place in addiction medicine's future leadership by building new fellowships. This interactive workshop will equip participants with a step-by-step road map for fellowship development, including identifying key team members, cultivating relationships with institutional partners, and designing clinical and didactic curricula. The requirements for fellowship accreditation will be explained, and particular attention will be devoted to the policies of the Accreditation Council for Graduate Medical Education (ACGME). Concrete examples will be provided from operating fellowships so participants will have a better understanding of key issues such as rotation design and budgeting. The importance of incorporating prevention and early intervention into training will be explained, and Addiction Medicine Foundation representatives will also offer updates on recent developments that have implications for areas such as fellowship funding. The workshop, therefore, will be of value to administrators and other health professionals, as well as physicians. Questions and open discussion will be encouraged throughout, and participants who wish will be linked with the Addiction Medicine Foundation's National Center for Physician Training in Addiction Medicine for ongoing technical assistance with fellowship development.

    Richard Blondell

    MD, MPH, FASAM

    Richard Blondell graduated from the University of Rochester school of medicine In 1978, and completed a family medicine residency at the University of Louisville in 1981. Following some time in private practice, he returned to the University of Louisville in 1985 and served as the director of the residency program from 1989 until 1997. After a sabbatical, he completed the certification requirements of the American Society of Addiction Medicine in 1998. Subsequently, he developed and directed a consult service on addiction medicine at the University of Louisville Hospital from 1998 to 2003. In 2003 he moved the University of Buffalo to pursue research interests in addiction medicine. He has served as a member of the Board of Directors of the American Board of Addiction medicine since 2007 and coordinates the Addiction Medicine Fellowship accreditation activities for ABAM-Foundation. No disclosures

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    Randall Brown

    MD, PhD, DFASAM

    Dr. Brown is on the Board of Directors of The Addiction Medicine Foundation and is President-Elect of the Addiction Medicine Fellowship Directors Association. He is Board Certified in Family Medicine and Addiction Medicine. He has been heavily involved in fellowship development at the program for which he was the founding Director at the University of Wisconsin School of Medicine and Public Health, as well as at the national level. He serves as a consulting physician in addiction medicine at UW Hospital (where he is the Director of the Center for Addictive Disorders), William S. Middleton Memorial Veterans Hospital, the UW Hospital HIV/AIDS Clinic, and at Access Community Health Centers (a network of Federally Qualified Health Centers). Dr. Brown is also the Director of the UW SMPH fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin. Dr. Brown holds a PhD in Population Health Sciences from the University of Wisconsin.

    Andrew Danzo

    BA

    Mr. Danzo is Coordinator of the ABAM Foundation National Center for Physician Training in Addiction Medicine. He is also Associate Director of Program Development in the University at Buffalo Primary Care Research Institute and research instructor in the University at Buffalo Department of Family Medicine.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - ACOG - Kansas City, MO - Sunday, July 15, 2018

    Contains 23 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.

    image



    image


    Sunday, July 15, 2018 | 1:00 pm - 5:30 pm

    Sheraton Kansas City at Crown Center
    2345 McGee St
    Kansas City, MO 64108
    Click here to register for the course.
    Cost: $75

    This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

    Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed. 

    Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

    Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

     

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FASAM Chair

    None

    Edwin A. Salsitz, MD, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None



    Noel Ilogu, MD, MRCP

    None

    Abigail Kay, MD

    None

    John Tanner, DO, FASAM

    Reckitt Benckiser

    OREXO

    BDSI

    Honorarium

    Honorarium

    Honorarium

    Speaker

    Speaker

    Speaker and Consultant

    Catherine Friedman, MD

    None

    ASAM Buprenorphine Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Section Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Edwin Salsitz, MD, FASAM

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None


    ASAM Buprenorphine Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin Salsitz, MD, FASAM

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Senior Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Dan A. Alford, MD, MPH

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None

    Sarah Bagley, MD

    ASAM Millennium Fellowship Award

    Partial Salary Support

    Awardee

    Alexander Y. Walley, MD, MSc

    None

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None

    Learners will be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction
    1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
    2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
    3. Continue to Module 1 Part 2 and Module 1 Part 3
    4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
    5. After you have completed Module 1 Quiz, continue to modules 2 and 3
    6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
    7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - ACOG - Princeton, NJ - Friday, June 29, 2018

    Contains 24 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.

    image



    image

    image


    Friday, June 29, 2018 | 9:30 am - 2:30 pm

    New Jersey Hospital Association
    760 Alexander Rd
    Princeton, NJ 08540
    Cost: $75

    **This course is offered for free to NJ physicians, advance practice nurses, physician assistants, certified nurse midwives, please contact Angela Centellas, acentellas@njha.com, for more information. 


    This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

    Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed. 

    Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

    Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

     

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FASAM Chair

    None

    Edwin A. Salsitz, MD, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None



    Noel Ilogu, MD, MRCP

    None

    Abigail Kay, MD

    None

    John Tanner, DO, FASAM

    Reckitt Benckiser

    OREXO

    BDSI

    Honorarium

    Honorarium

    Honorarium

    Speaker

    Speaker

    Speaker and Consultant

    Catherine Friedman, MD

    None

    ASAM Buprenorphine Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Section Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Edwin Salsitz, MD, FASAM

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None


    ASAM Buprenorphine Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin Salsitz, MD, FASAM

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Senior Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Dan A. Alford, MD, MPH

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None

    Sarah Bagley, MD

    ASAM Millennium Fellowship Award

    Partial Salary Support

    Awardee

    Alexander Y. Walley, MD, MSc

    None

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None

    Learners will be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction
    1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
    2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
    3. Continue to Module 1 Part 2 and Module 1 Part 3
    4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
    5. After you have completed Module 1 Quiz, continue to modules 2 and 3
    6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
    7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - ACOG - Champaign, IL - Monday, December 3, 2018

    Contains 24 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.

    image



    image


    Monday, December 3, 2018 | 10:00 am - 2:30 pm

    Carle at the Fields, Excellence Room
    3310 Fields S. Dr. 
    Champaign, IL 61822

    Cost: $100

    This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

    Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed. 

    Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

    Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

     

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FASAM Chair

    None

    Edwin A. Salsitz, MD, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None



    Noel Ilogu, MD, MRCP

    None

    Abigail Kay, MD

    None

    John Tanner, DO, FASAM

    Reckitt Benckiser

    OREXO

    BDSI

    Honorarium

    Honorarium

    Honorarium

    Speaker

    Speaker

    Speaker and Consultant

    Catherine Friedman, MD

    None

    ASAM Buprenorphine Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Section Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Edwin Salsitz, MD, FASAM

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None


    ASAM Buprenorphine Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin Salsitz, MD, FASAM

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Senior Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Dan A. Alford, MD, MPH

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None

    Sarah Bagley, MD

    ASAM Millennium Fellowship Award

    Partial Salary Support

    Awardee

    Alexander Y. Walley, MD, MSc

    None

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None

    Learners will be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction
    1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
    2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
    3. Continue to Module 1 Part 2 and Module 1 Part 3
    4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
    5. After you have completed Module 1 Quiz, continue to modules 2 and 3
    6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
    7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Evaluation and Certificate - ASAM 48th Annual Conference

    Contains 2 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

    Download the CME Tracking Sheet to assist with recording sessions attended at the conference. Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Washington, DC - Saturday, August 25, 2018

    Contains 2 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices. This course is SAMHSA-supported and meets the requirements needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    image

    Saturday, August 25, 2018 | 8:00 am - 5:30 pm

    Howard University
    The Louis Stokes Health Sciences Library
    501 W Street, NW
    Washington, DC 20059

    Cost: FREE

    Registration Deadline: Friday, August 17, 2018

    Hosted by:

    Howard University
    (Honorarium, Meals & Free Parking provided) 

    image


    Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    This FREE 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physicians, nurse practitioners, and physicians assistants who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders in Washington, DC. You must be licensed in Washington, DC or plan to obtain a license in Washington, DC to attend this course. This course is SAMHSA-supported and meets the requirements needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office ‐ based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

    For NPs (CE Credit through AANP): Click Here
     
    For PAs (AAPA Category 1 CME Credit): Click Here


    Click here to view additional resources.

    Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    At the conclusion of this activity, learners should be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Licensed physicians, nurse practitioners, and physician assistants in the Washington DC area who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.



    1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

      1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

    4. Choose the type of credit (Physician or Non-physician) and click submit

    5. Click the button “View/Print Certificate” to save or print your certificate
      1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


    Click here for more information on applying for a waiver to prescribe buprenorphine.

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Johns Hopkins Nursing - Saturday, September 22, 2018

    Contains 3 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices. This course is SAMHSA-supported and meets the requirements needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    image

    Saturday, September 22, 2018 | 8:00 am - 5:30 pm

    Johns Hopkins School of Nursing
    Pinkard Building, Room 217
    525 N. Wolfe Street
    Baltimore, MD 21205

    Cost: FREE

    Hosted by: 
    Johns Hopkins School of Nursing


    Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physicians, nurse practitioners, and physicians assistants who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office ‐ based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

    For NPs (CE Credit through AANP): Click Here
     
    For PAs (AAPA Category 1 CME Credit): Click Here


    Click here to view additional resources.

    Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    At the conclusion of this activity, learners should be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Licensed physicians, nurse practitioners, and physician assistants who wish to treat patients with opioid use disorder and to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.



    1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

      1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

    4. Choose the type of credit (Physician or Non-physician) and click submit

    5. Click the button “View/Print Certificate” to save or print your certificate
      1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


    Click here for more information on applying for a waiver to prescribe buprenorphine.

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.